# TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF) — divestiture/asset_sale [announced]
Source: SEC API (secapi.ai) · situation sit_e6fc2e89b813e9a5e68f · retrieved 2026-08-11T15:53:11.752Z

## Overview
Teva Pharmaceutical Industries Limited is a leading innovative biopharmaceutical company enabled by a world-class generics business, with key innovative brands including AUSTEDO, AJOVY, and UZEDY, and a robust biosimilars portfolio.

Teva Pharmaceutical Industries Limited announced the replacement of its American Depositary Share (ADS) program with a direct listing of its ordinary shares on the New York Stock Exchange (NYSE). ADSs will be exchanged on a one-for-one basis for ordinary shares, with ordinary shares commencing trading on the NYSE on Monday, September 14, 2026, after ADSs cease trading at the close of trading on Friday, September 11, 2026. The transition aims to broaden Teva's shareholder base, support potential inclusion in leading indices, and optimize cost-of-capital. There is no impact to Teva's ordinary shares traded on the Tel Aviv Stock Exchange (TASE).

## Key dates
- Announced 2026-07-29 · Expected close 2026-09-14

## Timeline
- 2026-07-29 · 8-K (0001171843-26-004974): 8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD — *Teva Pharmaceutical Industries Limited is a leading innovative biopharmaceutical company enabled by a world-class generics business, with key innovative brands including AUSTEDO, AJOVY, and UZEDY, and a robust biosimilars portfolio.* Teva Pharmaceutical Industries Limited announced the replacement of its American Depositary Share (ADS) program with a direct listing of its ordinary shares on the New York Stock Exchange (NYSE). ADSs will be exchanged on a one-for-one basis for ordinary shares, with ordinary shares commencing trading on the NYSE on Monday, September 14, 2026, after ADSs cease trading at the close of trading on Friday, September 11, 2026. The transition aims to broaden Teva's shareholder base, support potential inclusion in leading indices, and optimize cost-of-capital. There is no impact to Teva's ordinary shares traded on the Tel Aviv Stock Exchange (TASE).
  https://www.sec.gov/Archives/edgar/data/818686/0001171843-26-004974.txt

## Citations
- 0001171843-26-004974 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000117184326004974